Blood – components, testing & collection market

BLOOD-COMPONENTS, TESTING & COLLECTION MARKET SIZE
Scope of the Study
This report gives an insight on different areas of Blood – Components, Testing & Collection. Blood Research
and Products include Blood Products, Blood Banking Devices (Such as Equipment involved in Collecting,
Processing and Storing Blood and Blood Components), Blood Testing and Other (Such as Artificial Blood, Cord
Blood and Recombinant Factors). Blood Products include Cellular Blood Components, Whole Blood and
Plasma Derived Products (Immunoglobulins, Coagulation factors, Alpha-1 proteinase inhibitors, Albumins,
Fibrin and Anti-Coagulants). Blood Testing includes Immunoassays, NAT and Other. The report provides an
in depth analysis of each of the type and product areas by their respective categories. The study includes
estimates and projections for the total global Blood Research and Products market and also key regional
markets that include North America, Europe, Japan, Asia-Pacific and Rest of World. Estimates and
projections are illustrated graphically.
Business profiles of 42 major companies are discussed in the report. The report serves as a guide to global
Blood industry, as it covers more than 213 companies that are engaged in Blood Products R&D, discovery,
testing and supply of products and services. Major Contract Research Organizations serving Blood Products
industry are also covered in the Corporate Directory section of this report. Information related to recent
product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also
covered in the report.
Blood Research and Products report is an ideal research tool providing strategic business intelligence to the
corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies,
contract research organizations, biotechnology companies and drug approval authorities in --
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets

Analytics and Data Presented in this Report Pertain to Several Parameters Such as –
 Global And Regional Market Sizes, Market Shares, Market Trends
 Product (Global And Regional) Market Sizes, Market Shares, Market Trends
 Technology Trends
 Corporate Intelligence
 Key Companies By Sales, Brands, Products
 Consumer Behavioral Patterns
 Other Strategic Business Affecting Data
Research Methodology
RI Technologies publishes business intelligence reports by going through a cycle of diligent research and
analysis activity. Research is done using both online and offline resources. The study outline of this report is
sketched on the following lines – global market analysis, regional market analysis, product segmentation,
global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape,
technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also
helpful for doing market evaluations, and estimating the market size for the future.
This report is uniquely researched and the methodology includes:
 Need and Scope of Study
 Product Definitions
 Segmental Analysis
 Regional Analysis
 Exclusive Data Analytics
 Corporate Intelligence
 Feedback
Right from concept to final compilation of this report, both primary and secondary research methods are
applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the
information for authentication of our own findings. Secondary research includes government publications,
investment research reports, web based surveys, website information of both companies and markets, and
other offline resources such as print publications and CDs.
Our compilation of easy to navigate PDF reports is essential value addition resources for leading and
growing companies.

II. REPORT SYNOPSIS
Introduction to Blood
Blood is a fluid tissue made of a fluid matrix called plasma in which blood corpuscles are suspended. Blood
corpuscles include red blood cells [RBCs] or erythrocytes, white blood cells [WBCs] or leukocytes and
platelets. Mature erythrocytes in circulation are non-nucleated and play a role in the transport of oxygen to
tissues. Leukocytes are broadly divided into granulocytes and agranulocytes. Granulocytes are basophils,
eosinophils and neutrophils, while agranulocytes are lymphocytes and monocytes.. Blood also contains a
small number of stem cells which can differentiate into other types of blood cells. Leukocytes play different
roles and are important in immune response. Blood platelets are involved in hemostasis or blood
coagulation.
Functions of Blood
Functions of blood can be grouped under three headings of transport, regulation and protection.
Transport Functions
These functions include the following:
 A continuous exchange of components of blood with tissue fluids develops a balance between
electrolyte and fluid.
 Blood carries hormones from the endocrine system to the target organs or cells inside the body.
 Blood carries waste products from cells to the exterior principally through the kidneys.
 Blood carries CO2 from different areas of the body to the lungs.
 Blood carries O2 and other nutrients to different areas of the body
 Blood enables the elimination of waste like lactic acid, urea and CO2.
 Blood delivers nutrients to different areas of the body from the digestive system
Regulation Functions
These functions include the following:
 Blood participates in pH regulation via the action of buffers.
 Blood plays an essential role in electrolyte and fluid balance. This takes place as the plasma proteins
and salts promote osmotic pressure
 Blood helps in regulation of body temperature. This is accomplished by eliminating heat from active
areas like the skeletal muscles and carrying the same to the skin or other areas from where dissipation
of the heat occurs.

Protection Functions
These functions include the following
 Blood maintains the temperature of the body by the circulation of heat.
 Blood protects the body from getting infected or injured through the inflammatory mechanism.
 Blood protects the body against aggression from foreign living organisms through the generation of
antibodies and white blood cells.
 Blood protects the body against disease via antibodies in blood plasma that react with the agents of
aggression.
 Blood aids in defending the body against microorganisms by the generation of phagocytic white-blood
cells that devour and destroy them.
 When blood vessels get damaged the blood clotting mechanism presents itself to prevent loss of fluid
via hemorrhage.
Hematology
A branch of biology or physiology, pathology, clinical laboratory, internal medicine and pediatrics that is
related to the study of blood, the blood producing organs and blood disorders is called hematology or
haematology. Hematology involves the study of etiology, diagnosis, treatment, prognosis and prevention of
blood disorders.
Blood disorders disrupt the mechanism of formation of blood and its constituents like blood cells,
hemoglobin, blood proteins and the system of coagulation.
Standard Clinical Hematology Tests
The complete blood count or the CBC is also called full blood count or the FBC. It is a test which involves
white blood cell count, platelet count, hemoglobin level and several factors involving red blood cells.
Coagulation is a specialty under hematology. Standard coagulation tests include the prothrombin time or
the PT and partial thromboplastin time or the PTT. Another popular hematology test is the erythrocyte
sedimentation rate or the ESR.
The Coombs test is a standard test conducted in a blood bank.
Categories of Hematological Disorders
Some of the significant hematologic disorders may be segregated as follows:
 Hemoglobinopathies – a congenital abnormality of the hemoglobin molecule or of the rate of
hemoglobin synthesis.
 Anemia which is the lack of red blood cells or hemoglobin.
 Hematological malignancies.
 Coagulopathies which are disorders of bleeding and coagulation.

Analyzing Hematological Disorders
Some of the various methods employed to analyze hematological issues are:
 Full blood count
 Erythrocyte sedimentation rate or the ESR
 Blood film
 Bone marrow examination
 Coombs test
 Diascopy
 Serum Ferritin level
 Vitamin B12 and Folate levels
 Prothrombin time
 Partial thromboplastin time
 Protein electrophoresis
 Hemoglobin electrophoresis
 D-dimer
 EOS
Therapies for Hematological Disorders
Some of the therapies for hematologic disorders are:
 Suggestions on diet
 Prescription pharmaceuticals
 Anticoagulation therapy.
 Intramuscular injections, Vitamin B12 injections
 Blood transfusion (anemia)
 Venesection (iron overload or polycythemia)
 Bone marrow transplant (leukemia)
 Chemotherapy (leukemia)
 Radiotherapy (leukemia)

Segmentation of Blood – Components, Testing & Collection Market
Exhibit 1. Segmentation of Global Blood – Components, Testing & Collection Market by Product Type
Product Type
Blood Components
Blood Testing & Collecting Devices
*Other
*Other Includes Artificial Blood and Research
© RIT, 2013
Exhibit 2. Segmentation by Blood Components & Blood Testing and Collecting Devices
Blood Components Blood Testing and Collecting Devices
Plasma Products Management and Monitoring Instruments
Cellular Components Immunoassays
Whole Blood ^Other
^Other Includes Nucleic Acid Test (NAT) and Blood Grouping
© RIT, 2013
The term “Blood – Components, Testing & Collection refers to Blood Components, Blood Collection Devices
and Blood Testing Equipment employed during blood transfusion, collection / storage and microbial
detection.

III. MARKET DYNAMICS
Market Overview
Europe and the US together account for almost 2/3rd of global Blood – Components, Testing & Collection
market. The blood components market is estimated to constitute about XX% of the global market in 2015.
Automated blood collection and processing systems as well as prior-screening capabilities of latest assays
are expected to enhance quantity and quality of blood.
Global Market Analysis
The global Blood – Components, Testing & Collection market is predicted to touch US$XX billion by 2020 at
a CAGR of 11.54%, from an estimated US$XX billion in 2012. North America is the largest market with a
share of XX% closely followed by Europe and Japan with XX% and XX% respectively. Asia-Pacific market is
projected to represent the fastest growing market with a CAGR of XX% throughout the analysis period.
Japan represents the second fastest growing market closely followed by Europe and North America at a
CAGR of XX% and XX% respectively.

Exhibit 3. Blood - Components, Testing & Collection – Global Value Market Estimations & Predictions
(2005 -2020) by Geographic Region for North America, Europe, Japan, Asia-Pacific and Rest of World in
US$ Billion
Year/Region North America Europe Japan Asia-Pacific Rest of World Total
2005 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX 11.54
© RIT Figures, 2013
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Billion
North America Europe Asia-Pacific Latin America Rest of World

Exhibit 4. Blood - Components, Testing & Collection – Global Value Market Shares (2010, 2015 & 2020) by
Geographic Region for North America, Europe, Japan, Asia-Pacific and Rest of World
Year/Region North America Europe Japan Asia-Pacific Rest of World Total
2010 XX.XX XX.XX XX.XX XX.XX XX.XX 100
Tainted Blood Products and Affected Hemophiliacs
Hemophilia or bleeders disease is a hereditary disorder and the mutant gene responsible for it is X-
chromosome linked. The disorder arises as a result of deficiency of clotting factors that are necessary for
blood coagulation. In type hemophilia-A clotting factor VIII is wanting while in hemophilia-B clotting factor
IX is deficient. Hemophilia-A is more common than the other. Since it is an inherited disease there is no
permanent cure. But injection of the deficient clotting factor will be the remedy. Some people need it
almost every alternate day.
Tainted Blood Products and Health Hazard
There have been several instances that exposed the callous attitudes of certain pharmaceutical companies
that manufactured blood products contaminated with HIV [human immunodeficiency virus] and HCV
[hepatitis C virus] and marketing them despite knowing the truth. Health havoc was caused to several
hemophiliacs who were administered these blood products.
Clotting factors were manufactured and introduced into the market by US based Armour Pharmaceutical
Company, Cutter Biological division of Bayer Corporation, Hyland Pharmaceutical division of Baxter

International and Alpha Therapeutic Corporation. In earlier days [late 1970s to early 1980s] there was no
proper procedure available to detect the presence of HIV in blood samples.
Earlier it was thought AIDS spreads only by homosexual behavior and IV drug injections. But in mid 1980s
USCDCP [United States Centers for Disease Control and Prevention] reported the occurrence of this disease
in three hemophiliacs. This raised the suspicion that AIDS is perhaps transmitted via blood products. But
lack of sensitive detection test for HIV in the blood samples of donors stood in the way to establish
transmission of this disease from plasma donors. By the beginning of the year 1983, evidences pointed out
the plasma products as the source of HIV transmission. Subsequently, USCDCP strongly criticized the
manufacturers of blood products as responsible for the prevalence of AIDS in hemophilia patients. The use
of tainted blood products manufactured in US not only affected hemophiliacs in US, but also in other
countries that imported them. Though the number of people who developed the diseases varied from one
country to another, the contributory factors for the development and spread of the blood borne diseases
were almost similar.
Exhibit 5. List of Global Major Companies
Company Name Region Website
Affinity Biologicals Canada www.affinitybiologicals.com
Astrazeneca, Plc UK www.astrazeneca.com
BioTime, Inc. USA www.biotimeinc.com
Caridian BCT, Inc. USA www.caridianbct.com
Cord Blood Registry USA www.cordbloodbank.com
CSL Behring USA www.cslbehring.com
Daxor Corporation USA www.daxor.com
Fresenius SE Germany www.fresenius.se
Fujirebio Diagnostics, Inc., USA www.fdi.com
Gambro AB Sweden www.gambro.com
Gen-Probe, Inc. USA www.gen-probe.com
More….

Type Analysis by Blood Products
During the analysis period 2005-2020, the global market for Cellular Blood components is projected to
remain the largest among all other Blood Products with a market share of XX.XX % by 2020. In terms of
market value, Cellular Blood components are estimated at US$ XX.XX billion for 2012 and are projected to
reach US$ XX.XX billion by 2020. Plasma Derived products is expected to register the fastest growth during
the analysis period with a CAGR of XX.XX %.
Exhibit 6. Blood Components - Global Value Market Estimations & Predictions (2005 -2020) by Type for
Plasma Products, Cellular Components and Whole Blood in US$ Billion
Year/Type Plasma Products Cellular Components Whole Blood Total
2005 XX.XX XX.XX XX.XX XX.XX
%CAGR XX.XX XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Billion
Plasma Products CellularComponents Whole Blood

Exhibit 7. Blood Products - Global Value Market Estimations & Predictions (2005 -2020) by Type for Blood
Components, Blood Testing & Collecting Devices and *Other in US$ Billion
Year /Products Blood Components Blood Testing & Collecting Devices Other Total
CAGR% XX.XX XX.XX XX.XX 11.54
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Billion
Blood Components Blood Testing& Collecting Devices Other

Exhibit 8. Blood Products – Global Value Market Shares (2010, 2015 & 2020) by Type for Blood
Components, Blood Testing & Collecting Devices, and *Other
Year /Products Blood Components Blood Testing & Collecting Devices Other Total
2010 XX.XX XX.XX XX.XX 100

Analysis of Global Plasma Products by Type
Global Blood Plasma Products market was estimated at US$XX billion in 2012 and is projected to touch US$
XX billion by 2020 at a CAGR of XX%.
Global Immunoglobulin market is the largest product segment valued at US$XX billion in 2012 and is
projected to reach US$XX billion by 2020. Blood Clotting factors market is expected to reach US$XX billion
by 2020, registering a CAGR of XX% during the analysis period 2005-2020.
Exhibit 9. Blood Plasma – Global Value Market Estimations & Predictions (2005 -2020) by Type for
Immunoglobulins, Clotting Factors, Albumin and #Other in US$ Billion
Year/ Type Immunoglobulins Clotting Factors Albumin Other Total
2005 XX.XX XX.XX XX.XX XX.XX XX.XX
CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX
#Other Includes Proteins & Minerals
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Billion
Immunoglobulins ClottingFactors Albumin Other

Exhibit 10. Blood Plasma – Global Value Market Shares (2010, 2015 & 2020) by Type for
Immunoglobulins, Clotting Factors, Albumin and #Other
Year/ Type Immunoglobulin Clotting Factors Albumin Other Total
2010 XX.XX XX.XX XX.XX XX.XX 100
#Other Includes Proteins & Minerals

Analysis by Blood Testing & Collecting Devices
Growing at a CAGR of XX%, Global Blood Testing and Collecting Devices market was estimated at US$XX
billion in 2012 and is projected to touch US$XX billion by 2020. Global Blood Management & Monitoring
Instruments market is projected to be the largest and fastest growing market during the analysis period
2005-2020.
Exhibit 11. Blood Testing & Collecting Devices - Global Value Market Estimations & Predictions (2005 -
2020) by Type for Management and Monitoring Instruments, Immunoassays and ^Other in US$ Billion
Year/Devices Management and Monitoring Instruments Immunoassays Other Total
CAGR% XX.XX XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Billion
Managementand Monitoring Instruments Immunoassays Other

Exhibit 12. Blood Testing & Collecting Devices - Global Value Market Shares (2010, 2015 & 2020) by Type
for Management and Monitoring Instruments, Immunoassays and ^Other
Year/Devices Management and Monitoring Instruments Immunoassays Other Total

MIR029: Blood – Components, Testing & Collection – A Market Insight Report, January 2012
© RI Technologies - www.researchimpact.com Sample Page - 18
IV. PRODUCT/TECHNOLOGY RESEARCH
Blood: The Life Stream in the Body
Blood is the most important and essential body fluid which is termed as a tissue in medical terms.
The various medical terms related to blood are derived from the Greek word hemo- and hemato. In
medical science, blood is defined as a special type of connective tissue which originates from the bones and
contains prospective molecular fibers in fibrinogen form
Blood is responsible for conveying the various nutrients, oxygen, minerals and other essential substances
into the various parts of the body. The blood donations carried out is aimed at saving the life of individuals
who have either lost blood in accidents or surgeries. Blood is also required to treat people with severely
low platelet count and anaemic condition. Effective screening and tests prior to administration of blood
help to maintain safety and minimize transfusion diseases. These safety measures help both the donor and
the recipient.
In case of vertebrates, the main component of the blood is a liquid substance called blood plasma. The
Plasma liquid contains around 60% of blood fluid. This fluid comprises of 90% water with dissolved minerals
ions, proteins, glucose, hormones, platelets, blood cells and carbon dioxide which plays a vital role in
conveying excretory products. The blood consists of two types of blood cells; they are red blood cells which
are commonly called as erythrocytes or RBC’s in short and white blood cells, called thrombocytes or WBC’s.
The most abundantly found cells in the vertebrate blood are the red blood cells. The red blood cell
comprises of haemoglobin which is a type of protein rich in iron content. It is mainly responsible for
conveying the oxygen by reversibly binding to the respiratory gas. It enhances the solubility in blood.
Further, the carbon dioxide content is completely conveyed using extra cellular dissolving in plasma in the
form of bicarbonate ion.
The blood of vertebrates appears bright red in colour due to the presence of haemoglobin.
 Some animals like molluscs and crustaceans make use of hemocyanin for conveying the oxygen in place
of haemoglobin.
 Similarly some of the insects and phylum molluscs make use of a typical fluid called haemolymph in
place of the blood. The only difference between this fluid and the blood is that fluid is not enclosed in a
circulatory system.
 Another important observation is in majority of the cases, this fluid does not contain the oxygen-
conveying substances like the haemoglobin. This is primarily because their body composition is very
small and their tracheal system is more than sufficient to convey oxygen to the various parts of the
body.
 The vertebrates containing jaws are exclusively designed. They possess an adaptive immune system
containing white blood cells on a majority.

 The white blood cells play prominent role in restricting the entry of parasites and defying infections.
 The blood clotting takes place due to the vital activities of Platelets.
 The phylum arthropods contain haemocytes as a prominent part of their immune system. They make
use of haemolymph in their immune system.
The circulation of blood inside the blood vessels takes place by the continuous pumping action of the heart.
In animals which contain lungs, the blood conveyed through the arteries also carries oxygen from inhaled
air to the various tissues of the body. Further, the exhaled air which contains carbon dioxide and waste
products of metabolism produced by cells is transported by the venous blood.
BLOOD – COMPONENTS, TESTING & COLLECTION – THE OUTLOOK
A sudden increase in new infections all over the world is a matter worry to the blood banking and blood
products industry. Even though the people were very alert regarding the different infections and health
workers tried to reduce the severity of the infection, the industry is yet to overcome difficulties like
security, and the accessibility to good quality blood. This knowledge has lead to very strict safety
measurements being taken for both the donors as well as the blood screening (blood) banks which has to
be adhered to before any transfusion is carried out. The risk of diseases spread via transfusions has
decreased by conduction of thorough testing and screening techniques and also with the assistance from
the latest technologies. The condition did improve on the whole but there are still cases of diseases being
transmitted through blood transfusions in developing as well as under-developed countries. Although there
were movements that were carried out in these countries, it was only criticized and very few donors
volunteered.
As more and more consumers are insisting in a zero-risk blood supply, large investments are being put into
the development of pathogen reduction solutions which is carried out by small biotechnology firms and
also large medical device manufacturers. Providing information which is associated with the efficiency and
safety levels of pathogen inactivation systems that arises from research labs as well as clinical setting will
give them an impetus for enhanced market penetration. The growth of new technologies which has the
ability to destroy a wide range of pathogens and at the same time not cause damage to the blood products
will probably improve the market expansion.
As new technologies are being developed, the pathogen reduction Blood market is not likely to face tough
competition. The technologies that were there earlier like solvent/detergent plasma were considered
unsafe and could not be generally applied whereas the new technologies will not considerably reduce the
window of time from the initial infection and the point at which the pathogen is identified.
The blood banks now readily await a safe technology that will combine with their processing systems and
decrease the danger of transfusion-related infections to almost nil. The success of the market is ascertained
by the capacity to provide cost-effective technologies with a wide kill range, strong safety profile and the
effortlessness in the application. The provision to persuade the buyer decision making processes combined
with first-mover advantage will be significant in achieving a competitive edge……

About RI Technologies
RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We
emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly
monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry
based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging
technologies in areas of discovery, design and development.
Research – As Good as the Methodology is!
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
© COPYRIGHT
The copyright and publication rights to all RI Technologies' reports and other products are the property of
the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of
the material without express permission is not allowed. The buyer, under no circumstances, shall license,
resell or repackage, or sell data without prior permission of the company.
DISCLAIMER
RI Technologies sells content in good faith. The company is not liable to the buyer for any implications
arising out of the usage of data for any particular purpose. The company makes no representations or
warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for
data compilation and presentation, the company does not accept any responsibility for findings in the study
which are a cumulative effort of primary and secondary research resources. The studies do not endorse or
promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are
not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage
of the data.

Blood – components, testing & collection market

Recommended

Recommended

More Related Content

More from Research Impact

More from Research Impact (11)

Recently uploaded

Recently uploaded (20)

Blood – components, testing & collection market